Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

59.71 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EDT, Mar 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9

...

87 88 Next >

Merck & Co. Trades Ex-Dividend as Healthcare Emerges as a Volatility Hedge in 2026

March 16, 2026

Amidst a backdrop of mounting geopolitical tensions and sharp swings in the broader indices, pharmaceutical giant Merck & Co. (NYSE: MRK) officially trades ex-dividend today, March 16, 2026. Investors...

Via MarketMinute

1 ETF That Could Turn $100 Per Month Into $67,380 ↗

March 15, 2026

How does solid growth -- plus a 3.3% dividend yield sound?

Via The Motley Fool

Topics ETFs Economy World Trade

Bristol-Myers Squibb Co. (NYSE:BMY): A High-Yield Dividend Stock for Income Investors ↗

March 13, 2026

Via Chartmill

1 S&P 500 Stock Worth Your Attention and 2 We Question

March 12, 2026

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...

Via StockStory

Topics Stocks

BioNTech Navigates Post-Pandemic Deficit: A €17 Billion Bet on the Oncology Frontier

March 10, 2026

In a watershed moment for the biotechnology sector, BioNTech SE (NASDAQ: BNTX) has reported its full-year 2025 financial results, signaling the definitive end of the COVID-19 vaccine gold rush and the...

Via MarketMinute

3 Healthcare Stocks Paying the Highest Dividends of 2026 ↗

March 10, 2026

A handful of the industry's income-generating gems are hiding in plain sight.

Via The Motley Fool

Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma

March 09, 2026

From Bristol Myers Squibb

Via Business Wire

Why Bristol Myers Squibb Stock Crushed it in February ↗

March 08, 2026

It delivered for shareholders in its fourth quarter of 2025 with a double beat on analyst projections.

Via The Motley Fool

Topics Intellectual Property

U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis

March 06, 2026

From Bristol Myers Squibb

Via Business Wire

2 Top Healthcare Dividend Stocks to Buy and Hold Forever ↗

March 05, 2026

These stocks can be slow-and-steady wealth compounders.

Via The Motley Fool

Topics Intellectual Property

Q4 Earnings Outperformers: Bristol-Myers Squibb (NYSE:BMY) And The Rest Of The Branded Pharmaceuticals Stocks

March 04, 2026

Via StockStory

Topics Artificial Intelligence Intellectual Property

IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook ↗

March 03, 2026

The founder criticized traditional chemotherapy approaches from Amgen and Bristol Myers and hyped up the mechanism behind Anktiva.

Via Stocktwits

Topics Artificial Intelligence

Bristol Myers Squibb Announces Dividend

March 02, 2026

From Bristol Myers Squibb

Via Business Wire

How to Spot Winning Innovation ↗

March 02, 2026

Author Lorraine Marchand stops by to chat.

Via The Motley Fool

Topics Artificial Intelligence

FourWorld Takes a Major Swing on Sable Offshore (SOC), Buying 8 Million Shares ↗

March 02, 2026

Specializing in offshore oil and gas, Sable Offshore Corp. operates three platforms and an onshore facility across 16 federal leases.

Via The Motley Fool

Topics Energy Lawsuit

Big Pharma Dividend Stock BMY Could Help Turn $100,000 Into a Seven‑Figure Retirement ↗

February 28, 2026

Bristol Myers Squibb has an attractive 4% yield and a strong dividend history.

Via The Motley Fool

Topics Intellectual Property

Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy

February 26, 2026

In a move that solidifies a new standard of care for a high-risk patient population, the U.S. Food and Drug Administration (FDA) has granted full approval to Pfizer Inc. (NYSE: PFE) for its BRAFTOVI...

Via MarketMinute

Topics Economy Intellectual Property

SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

February 26, 2026

From Bristol Myers Squibb

Via Business Wire

Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics

February 25, 2026

In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total...

Via MarketMinute

Topics Intellectual Property

Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity

February 24, 2026

EQNX::TICKER_START (NASDAQ:HELP),(CBOE:HELP),(NYSE:TAK),(NASDAQ:CMPS),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

3 Reasons to Avoid BMY and 1 Stock to Buy Instead

February 23, 2026

Over the past six months, Bristol-Myers Squibb has been a great trade, beating the S&P 500 by 22.8%. Its stock price has climbed to $61.33, representing a healthy 30.1% increase. This was partly due to...

Via StockStory

Topics Stocks

Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference

February 23, 2026

From Bristol Myers Squibb

Via Business Wire

European Commission Grants Marketing Authorization to Cytokinetics for Cardiac Drug MYQORZO

February 23, 2026

In a landmark decision for the cardiovascular treatment landscape, the European Commission (EC) officially granted marketing authorization to Cytokinetics, Inc. (Nasdaq: CYTK) on February 17, 2026, for...

Via MarketMinute

Topics Intellectual Property

Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia

February 23, 2026

From Bristol Myers Squibb

Via Business Wire

2 Large-Cap Stocks on Our Buy List and 1 That Underwhelm

February 22, 2026

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth...

Via StockStory

Down 25%, Should You Buy the Dip on Bristol Myers Squibb? ↗

February 21, 2026

The pharma industry's dreaded patent cliff is a key driver of the stock's decline.

Via The Motley Fool

Topics Intellectual Property

2 Incredibly Cheap Dividend Stocks to Buy Now ↗

February 19, 2026

Yes, there are bargains out there for investors seeking income-paying stocks.

Via The Motley Fool

Topics Intellectual Property

3 Stocks to Buy and Hold for 2026 and Beyond ↗

February 19, 2026

Any of these three pharmaceutical titans could move the needle in your portfolio.

Via The Motley Fool

Topics Economy Intellectual Property

Cytokinetics Secures Triple Crown: EU Approval of MYQORZO Solidifies Global Reach in Cardiovascular Market

February 19, 2026

Cytokinetics, Inc. (Nasdaq: CYTK) has officially cleared its final major regulatory hurdle for its flagship heart failure drug, MYQORZO (aficamten), receiving marketing authorization from the European...

Via MarketMinute

ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA

February 19, 2026

As of February 19, 2026, ImmunityBio, Inc. (NASDAQ: IBRX) stands at a pivotal crossroads between clinical ambition and commercial reality. Once a "story stock" fueled by the vision of its billionaire...

Via Finterra

Topics Lawsuit

< Previous 1 2 3 4 5 6 7 8 9

...

87 88 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.